Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single-dose nemolizumab in pediatric atopic dermatitis
jRCT2080223685Phase 1Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Maruho Co., Ltd. Primary endpoints: Safety and tolerability of single-dose nemolizumab and Pharmacokinetics of nemolizumab (tmax, t1/2). Started Oct 2017; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223685.